§ GLP-1 & Weight Loss
STEP 1
The pivotal randomized trial of semaglutide 2.4 mg for chronic weight management (NEJM, 2021).
Fact-checked 12 May 2026Plain-English Reference
STEP 1 was a 68-week, double-blind randomized trial of 1,961 adults with overweight or obesity (without diabetes). Participants on semaglutide 2.4 mg lost an average 14.9% of body weight versus 2.4% on placebo. STEP 1 is the basis for Wegovy's FDA approval.